TICKERNERD
Menu
GRDNGRDNHealthcare · Medical Care Facilities

GRDN Stock Forecast: Guardian Pharmacy Services, Inc. Price Predictions for 2026-2027

Last close, 25 Aug 2026
$37
−1.06% on the day

The 6 Wall Street analysts covering Guardian Pharmacy Services, Inc. hold a median 12-month price target of $50 — +32.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 82 of 100 as at 24 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$2.4B
Ticker Nerd rank
82 / 100
Median analyst target
$50
Analysts covering
6
Revenue$351.8M+2.2% y/y
Operating income$20.6M
Net income$22.1M
Free cash flow$25.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.6%
1M
−7.8%
YTD
+24.0%
1Y
+42.2%
From 52W high
−14.9%
From 52W low
+59.3%
$23
$44
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

GRDN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Guardian Pharmacy Services, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 24 Aug 2026
82 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
94
Momentum
90
Growth
86
Quality
74
Volatility
59
Issuance
55
Accruals
44
Size
34
Value
25

Revisions (94): Analysts have, on balance, been raising their forecasts.

Value (25): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

GRDN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GRDN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$25$30$35$40$45$50Oct 25Jan 26Apr 26Jul 26GRDNHigh $50Median $50Low $47

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $47Median $50High $50

The green dot is the last close — the median target sits +32.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
7 Aug 2026OppenheimerMaintainsOutperform$43 → $49
17 June 2026B of A SecuritiesMaintainsBuy—
17 June 2026B of A SecuritiesMaintainsBuy$42 → $47
17 June 2026Truist SecuritiesMaintainsBuy—
17 June 2026Truist SecuritiesMaintainsBuy$43 → $47
7 May 2026OppenheimerMaintainsOutperform—
27 Apr 2026B of A SecuritiesInitiatesBuy—
13 Apr 2026Truist SecuritiesMaintainsBuy—
30 Mar 2026JefferiesInitiatesBuy—
12 Mar 2026OppenheimerMaintainsOutperform—
12 Mar 2026Truist SecuritiesMaintainsBuy—
14 Jan 2026Stephens & Co.MaintainsOverweight—
14 Nov 2025Truist SecuritiesMaintainsBuy—
10 Oct 2025OppenheimerInitiatesOutperform—
26 Sept 2025Truist SecuritiesMaintainsBuy—
19 May 2025Truist SecuritiesReiteratesBuy—
11 Apr 2025Truist SecuritiesMaintainsBuy—
15 Nov 2024Truist SecuritiesMaintainsBuy—
22 Oct 2024Stephens & Co.InitiatesOverweight—
21 Oct 2024Truist SecuritiesInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GRDN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

GRDN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 25 Aug 2026, Guardian Pharmacy Services, Inc. returned +42.2% against +20.5% for the S&P 500, dividends included.

GRDN vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160Oct 25Jan 26Apr 26Jul 26GRDNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

GRDN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+3.4%
Analysts raising
4
Analysts cutting
0
Fundamentals

Guardian Pharmacy Services, Inc. (GRDN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
36.3×

Cheaper than 22% of US stocks

Price / sales
1.6×

Cheaper than 58% of US stocks

Price / book
10.8×

Cheaper than 10% of US stocks

EV / EBITDA
21.5×

Cheaper than 14% of US stocks

Growth & margins
Revenue growth (YoY)
2.2%

Higher than 32% of US stocks

Earnings growth (YoY)
142.2%

Higher than 87% of US stocks

Gross margin
22.8%

Higher than 25% of US stocks

Operating margin
3.5%

Higher than 51% of US stocks

Net margin
4.5%

Higher than 58% of US stocks

Returns & dividend
Return on equity
30.4%

Higher than 88% of US stocks

Return on assets
13.4%

Higher than 96% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Guardian Pharmacy Services, Inc. (GRDN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Guardian Pharmacy Services, Inc. has a market value of $2.4B and an enterprise value of $2.3B.

  • Revenue in the twelve months to 30 June 2026: $1.5B. The latest quarter grew 2.2% year on year.

  • Net income over the same four quarters: $66.5M, a 4.5% net margin.

  • Diluted earnings per share, trailing twelve months: $1.03.

  • Free cash flow in the twelve months to 30 June 2026: $79.8M.

  • Guardian Pharmacy Services, Inc. spent $30.3M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 63.3M.

  • Trailing P/E: 36.3×; forward P/E: 26.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Guardian Pharmacy Services, Inc. employs 3,600 people — $407K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

GRDN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Care Facilities
CompanyMarket capTKN rank
GRDNGuardian Pharmacy Services, Inc.$2.4B
82
ADUSAddus HomeCare Corp.$2.3B
96
MDPediatrix Medical Group, Inc.$2.2B
99
ACHCAcadia Healthcare Co., Inc.$2.6B
58
BKDBrookdale Senior Living, Inc.$2.9B
79
AVAHAveanna Healthcare Holdings, Inc.$3.0B
88
ASTHAstrana Health, Inc.$1.9B
66

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Guardian Pharmacy Services, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GRDN news & analysis

Guardian Pharmacy Services, Inc., to Participate in Upcoming Jefferies Healthcare Services Investor Conference

Business Wire · 19 Aug 2026neutral

Guardian Pharmacy Services, Inc. (NYSE: GRDN) announced it will participate in the Jefferies Healthcare Services Conference on Tuesday, September 15, 2026. President and CEO Fred Burke will take part in a fireside chat at 2:25 p.m. Central Standard Time, with a live audio webcast accessible to investors, analysts, media, and the public.

Why it matters — The company's participation and live webcast give GRDN watchers a scheduled opportunity to hear directly from its CEO about the business.

Guardian Pharmacy Services Q2 Earnings Call Highlights

MarketBeat · 8 Aug 2026positive

Guardian Pharmacy Services reported second-quarter revenue of $351.2 million, up 2% year over year, and adjusted EBITDA of $29.7 million, up 19%. The company said it continued to offset profitability pressure from Inflation Reduction Act-related drug pricing reductions.

Why it matters — The results show Guardian maintained revenue growth and improved adjusted EBITDA despite ongoing drug-pricing headwinds from the IRA, giving those following GRDN a read on its profitability trajectory.

Guardian Pharmacy Services, Inc. (GRDN) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Guardian Pharmacy Services, Inc. (GRDN) held its Q2 2026 earnings call, and the transcript of that call has been published on Seeking Alpha. The excerpt provided identifies the headline and source but contains no details from the call itself.

Why it matters — A GRDN watcher would care because the earnings call transcript is a primary source for management's discussion of the company's latest quarterly financial performance and outlook.

Guardian Pharmacy Services (GRDN) Q2 Earnings and Revenues Top Estimates

Zacks Investment Research · 7 Aug 2026positive

Guardian Pharmacy Services reported Q2 earnings of $0.29 per share, surpassing the Zacks Consensus Estimate of $0.26 per share and up from $0.23 per share in the same period a year earlier. Revenues also topped estimates.

Why it matters — GRDN watchers would care because the company delivered results above analyst expectations and improved year-over-year earnings.

Guardian Pharmacy Services Reports Second Quarter 2026 Financial Results; Raises Full-Year Guidance

Business Wire · 6 Aug 2026positive

Guardian Pharmacy Services reported second-quarter 2026 financial results, with revenue of $351.8 million (up 2% year-over-year), roughly 210,000 residents served (up 8%), and net income of $22.1 million, which includes an $8.5 million item. The company also raised its full-year guidance.

Why it matters — A GRDN watcher would note the company's raised full-year guidance and continued growth in both revenue and residents served as key indicators of its ongoing performance.

FAQ

Frequently asked questions about GRDN stock

What is the GRDN stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Guardian Pharmacy Services, Inc. have a median 12-month price target of $50, with estimates ranging from $47 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GRDN stock a buy right now?

Of the 6 analysts covering Guardian Pharmacy Services, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Guardian Pharmacy Services, Inc. 82 out of 100 across roughly 4,600 US stocks as at 24 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GRDN?

As at 24 Aug 2026, Guardian Pharmacy Services, Inc. ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (94 of 100).

Will GRDN stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +32.7% from the last close, and Ticker Nerd's factor model ranks Guardian Pharmacy Services, Inc. 82 out of 100 as at 24 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GRDN stock forecast for 2030?

No analyst covering Guardian Pharmacy Services, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GRDN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $47 to $50 over the next 12 months.

How has GRDN stock performed over the past year?

Guardian Pharmacy Services, Inc. returned +42.2% over the 12 months to 25 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Guardian Pharmacy Services, Inc. do?

Guardian Pharmacy Services Inc. is a company that provides comprehensive pharmacy services primarily focused on the long-term care and senior living sectors.

What is the latest news on GRDN?

The most recent item we track (Business Wire, 19 Aug 2026): "Guardian Pharmacy Services, Inc., to Participate in Upcoming Jefferies Healthcare Services Investor Conference". Guardian Pharmacy Services, Inc. (NYSE: GRDN) announced it will participate in the Jefferies Healthcare Services Conference on Tuesday, September 15, 2026. President and CEO Fred Burke will take part in a fireside chat at 2:25 p.m. Central Standard Time, with a live audio webcast accessible to investors, analysts, media, and the public.

Company

About Guardian Pharmacy Services, Inc.

Guardian Pharmacy Services Inc. is a company that provides comprehensive pharmacy services primarily focused on the long-term care and senior living sectors. Its primary function is to ensure the safe, efficient, and timely delivery of medications to residents in assisted living facilities, nursing homes, and other similar communities. Notable features of Guardian Pharmacy Services include personalized care plans, innovative pharmacy technology solutions, and a strong emphasis on regulatory compliance and medication safety. The company employs a collaborative approach, working closely with caregivers, healthcare professionals, and facility administrators to optimize pharmaceutical care outcomes. Guardian's services significantly impact the health management sector, contributing to improved quality of life for residents through tailored medication management systems. With a growing network of independent local pharmacies across the U.S., Guardian Pharmacy Services plays a vital role in the healthcare industry, addressing the unique needs of its clientele through specialization and dedicated service provision. The company's efforts in enhancing operational efficiencies and adopting advanced pharmacy practices underscore its market significance in delivering indispensable healthcare support.

CEO Mr. Fred P. Burke · 3,600 employees · United States · https://guardianpharmacy.com